Compare · ILMN vs MGEN
ILMN vs MGEN
Side-by-side comparison of Illumina Inc. (ILMN) and Miragen Therapeutics, Inc. (MGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and MGEN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN carries a market cap of $31.30B.
- ILMN has hit the wire 14 times in the past 4 weeks while MGEN has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 0 for MGEN).
- Company
- Illumina Inc.
- Miragen Therapeutics, Inc.
- Price
- -
- -
- Market cap
- $31.30B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 2014
- News (4w)
- 14
- 0
- Recent ratings
- 25
- 0
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ILMN
- Amendment: SEC Form SCHEDULE 13G/A filed by Illumina Inc.
- Director Meister Keith A. sold $61,093,041 worth of shares (280,091 units at $218.12) (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $58,142 worth of shares (267 units at $217.76), decreasing direct ownership by 2% to 14,029 units (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 360 shares, decreasing direct ownership by 0.88% to 40,567 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D covered exercise/tax liability with 150 shares, decreasing direct ownership by 1% to 14,296 units (SEC Form 4)
- SVP, Chief People Officer Leckman Patricia covered exercise/tax liability with 208 shares, decreasing direct ownership by 0.98% to 21,120 units (SEC Form 4)
- Chief of Global Operations Pegels Kevin Carl covered exercise/tax liability with 604 shares, decreasing direct ownership by 2% to 28,434 units (SEC Form 4)
- Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology
- Director Meister Keith A. sold $66,560,212 worth of shares (281,433 units at $236.50) (SEC Form 4)
- Illumina selected to help bring precision medicine into everyday healthcare in Singapore
Latest MGEN
- SEC Form SC 13G/A filed by Miragen Therapeutics, Inc.
- SEC Form SC 13G filed
- SEC Form SC 13G filed
- SEC Form SC 13G/A filed
- SEC Form SC 13G/A filed
- SEC Form 4 filed by L Joseph Turner
- SEC Form 4 filed by Evan Peter Harwin
- SEC Form 4 filed by S. Jeffrey Hatfield
- SEC Form 4 filed by Tomas Kiselak
- SEC Form 4 filed by Arlene Morris